Cargando…
Personalization of Chemotherapy for Metastatic Pancreatic Cancer
Erlotinib is an approved drug for the treatment of advanced pancreatic cancer; however, its survival benefit is small and its cost is high, and the decision to use the drug may often be personalized according to the patient’s background. A 72-year-old Asian man in good general condition chose gemcit...
Autores principales: | Sasahara, Yuriko (Ito), Narimatsu, Hiroto, Suzuki, Syuhei, Fukui, Tadahisa, Sato, Hideyuki, Shirahata, Nakao, Yoshioka, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116360/ https://www.ncbi.nlm.nih.gov/pubmed/25093005 http://dx.doi.org/10.4137/CCRep.S14478 |
Ejemplares similares
-
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis
por: Takumoto, Yuki, et al.
Publicado: (2022) -
The Role of Cancer Boards in the Treatment Decisions Regarding Chemotherapy
por: Nakamura, Sho, et al.
Publicado: (2016) -
Correction: Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
por: Takumoto, Yuki, et al.
Publicado: (2023) -
Long-term survival after a favorable response to anti-EGFR antibody plus chemotherapy to treat bone marrow metastasis: a case report of KRAS-wildtype rectal cancer
por: Nakamura, Sho, et al.
Publicado: (2017) -
Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan
por: Yuki, Takumoto, et al.
Publicado: (2022)